{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidaveojczh4qovfr4agc4sb2hlqoavgiaxnm2wtm72wnquzbugr4m",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mo6k4jeinls2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigjsucl4hu4pmss2v3vir4c2mam7pcligswmljcob4pquuaodonl4"
    },
    "mimeType": "image/jpeg",
    "size": 199161
  },
  "path": "/news/2026-06-glp-1s-elevated-fainting-dizziness.html",
  "publishedAt": "2026-06-13T10:30:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications. After starting GLP-1s, these patients experienced higher rates of dizziness, fainting and other events related to low blood pressure, also known as hypotension.",
  "title": "GLP-1s tied to elevated risk of fainting, dizziness"
}